Anders (@Anders_Research) header
Anders (@Anders_Research) profile picture

Biotech, tech, gold, critical minerals, and the end of the old world.

New York, NY
Joined April 2023
Photo by Anders (@Anders_Research)Photo by Anders (@Anders_Research)Photo by Anders (@Anders_Research)Photo by Anders (@Anders_Research)Photo by Anders (@Anders_Research)Photo by Anders (@Anders_Research)Photo by Anders (@Anders_Research)Photo by Anders (@Anders_Research)Photo by Anders (@Anders_Research)Photo by Anders (@Anders_Research)
Potentially the biggest advancement in GBM ever. Readouts in GBM, pancreatic, and skin in the next 3-6 months. 15+ ongoing trials globally. $1.3 billion market cap is pennies. $DRTS has to be the best r/r in biotech right now. New article. substacktools.com/sharex/xE4…
4
2
25
3,837
$DRTS GBM update includes 8 patients. All patients still alive at up to 11 months post-op. 5 of 6 evaluable patients achieved CR (83% CR rate). 6th patient with PR (50%+ reduction). Looking pretty fantastic…
Excited to share our first-in-human Alpha DaRT study for recurrent glioblastoma at #SNO2026! 8 patients treated, 100% implantation feasibility, and 5 complete responses among 6 evaluable patients! Encouraging early results! @OhioStateRadOnc @joshuapalmermd
4
1
13
1,856
This poster for $DRTS on the SNO website makes it seem like nothing new is being reported though... nitter.cf/Anders_Research/status…
$DRTS presenting a poster tonight (7:30pm) at Meeting of Society for Neuro-Oncology with an update on its glioblastoma data. Investor call scheduled for Monday morning. Unclear what the data will include and when it will be PR'd. Would be great if we got 6-10-month survival updates on the first three patients, AND some additional response data from newer patients...
2
6
1,751
$DRTS presenting a poster tonight (7:30pm) at Meeting of Society for Neuro-Oncology with an update on its glioblastoma data. Investor call scheduled for Monday morning. Unclear what the data will include and when it will be PR'd. Would be great if we got 6-10-month survival updates on the first three patients, AND some additional response data from newer patients...
1
3
1,539
Link not working in my previous post. To reiterate, I am POUNDING THE TABLE on $DRTS Readouts in GBM, pancreatic, and skin in next 3-6 months. Potential to be the biggest breakthrough ever in GBM. $1.3B MC and still basically unknown/unfollowed. andersresearch.substack.com/…
1
5
1
19
2,403
$DRTS US pancreatic cancer trial seemingly expanded in size once again to 50 patients. In April the trial was expanded from 30 to 40 patients. Now ClinicalTrials showing a change to 50 patients as of 8/24. FDA clearly working very closely with $DRTS. Data around YE26.
3
4
17
1,553
Wonderinf if gold $GLD needs to dip more considerably below $4k before it can start chugging upwards again. Not sure that little micro dip was enough to reset the table….
2
777
Given the data $DRTS's tumor agnostic Alpha DaRT therapy continues to report across multiple tumor types, It seems ~possible~ that the FDA will allow for an expedited clinical development pathway(s). Wouldn't be surprised if HNSCC moves to Phase 3... nitter.cf/Anders_Research/status…
Alpha Tau $DRTS HNSCC data is great: 100% ORR (44% CR) across 9 patients... But was definitely hoping for a larger sample size. Trial was to enroll up to 48 patients, but adaptive trial design called for halt after 6 responses (i.e. success)... Thesis continues to play out.
8
1,866
Alpha Tau $DRTS HNSCC data is great: 100% ORR (44% CR) across 9 patients... But was definitely hoping for a larger sample size. Trial was to enroll up to 48 patients, but adaptive trial design called for halt after 6 responses (i.e. success)... Thesis continues to play out.
1
1
1
6
3,255
Many not realizing that $DRTS' Alpha DaRTs isn't even competing with $RVMD's daraxonrasib. The two will likely be used in combination. Dara's 13 months mOS is great, a doubling vs. SoC, but you are still dying in a year... Not to mention DaRT's immunogenic effect (CPI combo)
3
13
1,339
A lot of new investors that don't quite know the $DRTS story selling it off on ASCO data. These data are from disparate, diversely-enrolled trials, with many patients not receiving full tumor coverage. And still Alpha DaRTs is delivering 11+ months mOS vs. 6 months SoC... The 17-month mOS from last chemo initiation is an interesting data point but difficult to interpret. The bottom line is that even at these levels Alpha DaRT is a major improvement in SoC that can be COMBINED with $RVMD's daraxonrasib because of its stellar safety. AND that the data from the US-based 40-patient pancreatic trial due around YE will likely look even better.
3
3
16
1,835
Najarian is on $DRTS now... And this post is getting close to 1 million views... $DRTS going full mainstream, and is down 12% today on ASCO data that was largely already reported. Have been increasing my already-large position size this morning. nitter.cf/AlphaTauInsight/status…
$DRTS Featured on Fox Business as it’s set to announce Pancreatic Cancer Survival Data on Monday (June 1) “Fox Business said it right: ASCO 2026 is the Super Bowl of oncology and Alpha Tau is the rising star in the game that is becoming impossible to ignore.”
1
5
1,299
$IMMX continues to shape up well, potentially curative treatment in AL amyloidosis (severely underserved). BUT a bit confused why the company raised this $150M... Especially after raising $100M in December. Had $80M at 3/31/26 and only burning ~$10M per quarter... Why are we diluting like 30%+ right now when we have cash, the trial has finished enrolling, and we only expect the stock price to move higher over the course of the year...? Strange...
4
5
2,564
ASCO abstract out. As I said, this data was already largely known. Most patients received only partial coverage of their tumors with Alpha DaRTs (most under 50%). Data from the 40-patient US trial (expected around YE26) will likely be much better. nitter.cf/Anders_Research/status…
Just FYI on $DRTS pancreatic cancer ASCO abstract coming out this afternoon: I am nearly certain that it includes no "new" data. The 58 patients to be included in the abstract appear to be a combination of the data already presented at ASCO GI (n=32) and DDW (n=26).
2
1,516
Just FYI on $DRTS pancreatic cancer ASCO abstract coming out this afternoon: I am nearly certain that it includes no "new" data. The 58 patients to be included in the abstract appear to be a combination of the data already presented at ASCO GI (n=32) and DDW (n=26).
1
1
8
3,383
Alpha Tau $DRTS is going to be a $10 billion company.
2
16
2,374
$IMMX back at ~ATH after reversing higher to +7% on the day. Enrollment completed in March, final data in Q3, BLA submission shortly after (likely already submitting data on rolling basis), and potential approval in 2027 (could be early 2027). Presenting at Jefferies in June.
1
5
1,155
$DRTS delivering complete responses in two of its first three GBM patients. As good as you could hope for, though not totally surprising given the data do date. Market cap approaching $1 billion. Will go much higher over time given-tumor agnostic tech (if +data continues).
4
925